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Abstract
The primary purpose of this research was to develop and evaluate the efficacy and feasibility of a 
brief, cost-effective family focused intervention to promote adaptive coping and quality of life 
throughout a parent's bone marrow transplantation (BMT). Targeted outcomes were cohesion, 
decreased use of avoidance coping, open communication, and effective management of emotional 
distress. Participants included an intervention group of 31 families and 29 families in a control 
group who received usual care. Each Family included the BMT recipient, a partner-caregiver, and 
children 10-18. The intervention included two dyadic sessions for the BMT recipient and the 
partner-caregiver, one individual session for the caregiver, and two DVDs for children. Statistical 
analyses indicated the intervention had a positive impact on at least one aspect of the adaptation of 
each family member. Caregivers reported the most distress but benefitted least from the 
intervention, whereas recipients and children reported improvement in distress. Ratings of 
satisfaction/acceptability were high with 97% responding they would recommend the intervention 
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to others. Plans for future research include increased intervention intensity for the caregiver, a 
larger more diverse sample, and implementation over an extended period post-BMT.
Keywords
quality of life; coping; adaptation; stress; preventive intervention; BMT; cancer
Introduction
Bone Marrow Transplantation (BMT) holds hope for treatment of cancers previously 
considered incurable, however, it is an exceedingly challenging and intrusive therapy. (1) It 
is associated with high levels of uncertainty and morbidity, and each family member along 
with the recipient, lives with the threat of unmet expectations and potential loss. It results in 
a crisis characterized by life-changing circumstances that disrupt family structure and 
interaction in ways that threaten the stability and the quality of life (QOL) of each member. 
(2-4) Therefore, being that it is the family which provides the milieu for the recovery and 
well-being of the recipient, it is the focus of this intervention.
A comprehensive review of 22 studies provides empirical evidence that the impact of BMT 
on surviving recipients results in a major psychological/social transition requiring 
individuals to revise their perspective of the world, themselves, and their future. (5) On the 
other hand, there has been minimal research concerning the psychological and social impact 
on family members and the family environment. Following hospital discharge, the family 
caregiver becomes the primary and often sole provider of physical care and emotional 
support for their spouse/partner. This is a time when recipients are particularly fragile and 
dependent, and unable to resume previous roles, however, there are few studies examining 
the vulnerability of these individuals who are crucial to the recipient's survival. They may be 
at the highest risk for development of secondary psychosocial morbidity, that is higher than 
the recipient, and at the same time they are essential to maintaining QOL within the family. 
(6)
A longitudinal study concerning the adaptation of 192 caregivers/partners of BMT recipients 
pre-hospitalization through one month following discharge, found although emotional 
distress declined it remained equivalent to the mean for psychiatric patients. (7) In an 
additional study based on qualitative interviews with 15 of these caregivers following 
discharge, they spoke of experiencing a lack of support and “having to go it alone”. (8)
Assessment of the impact of BMT on both recipients’ and caregiver partners’ satisfaction 
with their relationship over a one-year trajectory, found increasing disparity between them 
with caregivers reporting lower levels of satisfaction and higher levels of depression and 
anxiety. (6) Likewise, a study of family interaction found caregivers’ level of satisfaction 
with this dyadic relationship to be consistently lower than that of recipients as measured 
prior to hospitalization through one year following treatment. However, based on a “coping 
with partner” sub-scale, dyads who engaged each other in managing the stress of BMT 
scored more positively on the total Dyadic Adjustment Scale, pointing to the importance of 
enhancing mutual support within this relationship. (9)
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Distress experienced by children as a consequence of parental BMT has been minimally 
reported, however, many BMT recipients are young and have dependent children who must 
also adapt to the disruption. One study of 61 children between 10 and 18 years of age over a 
12 month trajectory indicated the pre-hospitalization, pre-transplant period during family 
preparation was the most distressing. (10) Data obtained by interview directly from children 
indicated negative self-esteem, disruption in the roles particular family members 
traditionally assume, use of disengagement coping by the child, and the mother as transplant 
recipient were most strongly associated with negative adaptation.
Given these findings pointing to the negative impact of BMT on each family member, and 
the lack of interventions focusing on the family, the primary aim was to fill this gap and 
develop, refine, and determine the feasibility of delivering a brief, effective intervention to 
minimize secondary psychosocial morbidity. Specifically, the intervention was designed to 
reduce the level of emotional distress, to facilitate supportive functioning within the family, 
and to promote adaptive coping, thereby positively impacting QOL.
Methods
Research Design and Participant Families
This study included an intervention group and a control group of families receiving 
treatment as usual for BMT who had participated in exploratory research examining the 
issues they confront. Those findings then provided the basis for development of the 
intervention. (7-10) The recruitment procedure, points of data collection in the BMT 
trajectory, and measures were the same for both groups which were then matched for the 
analyses on BMT type - allogeneic or autologous, gender of the recipient parent, and the 
presence of at least one child participant 10-18 living in the home.
The intervention group included 31 families meeting the following criteria: (1) a parent 
undergoing an allogeneic or autologous BMT for the first time for the treatment of cancer; 
(2) a designated spouse/partner family caregiver in a committed relationship for a minimum 
of one year prior to BMT; (3) at least one child 10 - 18 living in the home willing to 
participate; (4) family members able to read and write English who had no issues that would 
interfere with their participation.
Families for both groups were recruited in collaboration with the BMT team at an NCI-
designated cancer center using the same procedures. Approximately 72% of eligible families 
consented to participate in the exploratory study while approximately 78% consented to 
participate in the intervention study. Three families were recruited from a local community 
type hospital for the intervention group, and they received the same intervention by the study 
team. There were no statistical differences in the means of outcome variables in this group, 
and the feasibility of the intervention in these two types of healthcare settings was 
supported. Data were collected at the same time points in the BMT trajectory from the 
participants in both groups using the procedures and measures described below.
Data were collected from parents at three time points by self-report questionnaires that took 
approximately 40-45 minutes to complete: T1 - baseline prior to hospitalization and pre-
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intervention; T2 - one month following discharge and completion of the intervention; T3 - 
four months following discharge. Data were collected from child participants by telephone 
interviews. A single co-investigator conducted all child interviews for both groups at the 
same time points in the trajectory that data were obtained from the parents. The interviews 
were approximately 40 minutes.
Individual participants were compensated as follows: parents, $70 for the initial dyadic 
session, and $40 for each questionnaire; children, $25 for each data collection interview. 
Similar compensation for data completion was given to control participants. All procedures 
for both studies were approved by the Scientific Review Committee of the Indiana 
University Simon Cancer Center and the Institutional Review Board of Indiana University.
Measures
Demographics
Included were age, gender, race, education, marital status of the recipient and caregiver 
dyad, and type of transplant. See Table 1. A comparison of child participants in the two 
groups indicate they were highly similar. There were a greater number of males in both 
groups, the mean age for females in both groups and males in the control group was 16 
years, with the mean for males in the control group being 15 years. All child participants 
were 10 - 18 and lived with the recipient.
Measures of Variables in Figure 1
Figure 1 incorporates variables measured to indicate the responses of individual family 
members to the stress of BMT. It is based on the fundamental premise of system's theory 
that the response of each individual affects the responses of each other individual as well as 
interaction within the system. (17)
Participants in both the intervention and control groups completed the measures for each 
variable at the same time points in the trajectory, that is at each time point described above. 
The measures are described in Table 2.
Intervention Components and Procedures
This manualized intervention was designed to maximize consistency and replicability, 
optimize the efficiency of delivery, and minimize costs. It is brief and based on the premise 
that the response of each family member has an impact on each other member, as well as on 
interaction within the family unit; (17, 18) therefore, all family members including the BMT 
recipient, the caregiver, and children 10 through 18 years of age were included as active 
participants. The intervention included two sessions for the parental dyad, one individual 
session for the caregiver, and two DVDs for children. An initial joint session with the 
recipient and caregiver partner was conducted in person or by telephone in preparation for 
hospitalization prior to admission, but following the collection of baseline data. Aims were 
to minimize dysfunctional family coping, reduce avoidance, promote open communication, 
and prepare for change and disruption in family living. The first DVD was also given prior 
to admission for transplant, one for autologous and one for allogeneic transplant. Content 
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included information about BMT, what to expect when visiting the hospital, and the 
importance of sharing concerns within the family.
Given the severe distress experienced by family caregivers, session two was held in person 
during hospitalization with the caregiver parent alone. The focus was promotion of self-care, 
stress management, handling concerns of children, and potential issues following discharge 
of the recipient. At this time, a second DVD was provided for children focusing on 
expectations and potential issues following hospitalization, and needs of the recipient that 
require adjustment of all family members. Participants kept the DVDs, they were 
encouraged to go back to them to get questions answered, and we strongly encouraged 
parents to view each of the DVDs with their children at least once.
The third intervention session was conducted by telephone two to three weeks following 
discharge with the caregiver/recipient dyad. It included discussion of concerns that came up 
following discharge, review of coping strategies being used by the dyad, and outside 
referrals for continued support that were made when necessary. Consistency and quality of 
the sessions were evaluated by audio recording with the written consent of participants, and 
they were then randomly evaluated throughout the intervention.
Data Analysis and Results
Qualitative Analysis: Acceptance and Feasibility
We evaluated acceptance and feasibility of the intervention along with preliminary efficacy 
by the T2 questionnaire following discharge for both caregivers and recipients. There were 
no differences in acceptability between them and their data were aggregated. Ninety- two 
percent agreed or strongly agreed the intervention helped meet the needs of their family. 
Specifically, 76% of participants agreed or strongly agreed the intervention facilitated 
coping effectiveness, 79% that it strengthened communication and support within the family, 
74% that it increased feelings of personal control in managing daily life, and 84% agreed or 
strongly agreed the intervention enabled them to plan for change and help their children 
cope with stress. Regarding the intervention format, 92% responded the number and timing 
of sessions was adequate and appropriate, 90% agreed they were able to use the information, 
and 97% would recommend the intervention to others. Satisfaction among the children was 
gauged by consistency of participation. The only child participants in the intervention group 
who dropped out were those whose families dropped out primarily due to the decline and/or 
death of the recipient.
Statistical Analysis
Demographic differences between the intervention and control groups were analyzed using 
the independent two samples t-test for continuous variables and a Chi-square test (Fisher's 
exact test) for categorical variables (Table 1). Statistics were conducted to examine the 
baseline data for significant differences (Table 3). There were no significant differences 
other than BMT type and we matched for that as explained below. Furthermore, due to the 
need to restrict the number of variables in the analysis only data from the oldest child in 
each family were included.
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For all outcomes, if an item was missing an imputed mean was assumed for that item based 
on the mean of available items for an individual when at least 50% of the items for that 
outcome were not missing. The sample size available from each group for the analyses at 
each data point is given in Table 4.
Twenty-nine families were enrolled in the control group and 31 in the intervention group. 
There were no families in the control group that could be matched with those in the 
intervention group based on the gender of the BMT recipient and type of transplant, that is, 
female autologous recipients. Therefore, to maximize the sample size and balance the two 
groups, families were stratified into three subgroups: male/allogeneic BMT, male/autologous 
BMT, and female/allogeneic BMT. (19) Within each subgroup and within each family 
member, recipient, caregiver, and child, outcomes were analyzed using a linear mixed model 
for repeated measures that included group, time, and their interaction. Estimated means at 
each time point were obtained. Overall estimated means and standard errors were calculated 
by weighting across three subgroups according to their respective sample sizes. 
Consequently, within-group and between-group Cohen's d effect sizes were derived. 
Thresholds for interpretation of Cohen's d included effect sizes labeled as large (d ≥ 0.80), 
medium (0.50 ≤ d < 0.79), and small (0.20 ≤ d < 0.49). (20) Data were analyzed using SAS 
9.4.
Results
To summarize sample characteristics, there were more men than women recipients, more 
Caucasians, and most dyads were married. Ninety-eight percent attended high school or 
greater. The primary difference between groups was more recipients in the intervention 
group received an allogeneic BMT, generally associated with greater challenges.
Within-group and between group results on each outcome for both the intervention and 
control groups are shown in Table 5. Growth in cohesion was significantly marked with 
small effect sizes for the intervention group. Four months from baseline both recipients 
(d=0.43) and caregivers (d=0.23) experienced an increased sense of cohesion. Decreased 
emotional distress was evident for recipients in the intervention group at one month (d=0.30) 
and four months (d=0.47), and for control group recipients at four months (d=0.27). Both 
intervention (d= 0.27) and control (d= 0.34) group caregivers experienced decreased distress 
at one month. Children in both groups also experienced decreased distress at one month 
(d=0.24 for the intervention group, and d= 0.27 for controls). A decrease in the use of 
avoidance coping was significantly marked with small effect sizes with less avoidance 
coping by recipients in the intervention group at one month (d=0.33), and children in the 
intervention group at one month (d=0.34) and four months (d=0.35). An increase in 
expressiveness was displayed both by caregivers (d=0.20) and children (d=0.28) in the 
intervention group at four months.
Summarizing, between-group results at one and four months based on Table 5, for recipients 
small effect sizes were seen favoring the intervention group for cohesion at four months 
(d=0.38), emotional distress at one month (d==0.21) and four months (d=0.22), and 
avoidance coping at one month (d=0.40). Among caregivers, small effect sizes favored the 
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intervention group for cohesion (d=0.24) and expressiveness (d=0.24) at four months while 
the effect size for emotional distress favored the control group (d=0.25) at four months. 
Among children, small effect sizes favoring the intervention group were seen for avoidance 
coping at one month (d=0.27) and expressiveness at four months (d=0.28), while a small 
effect size favoring the control group was seen for cohesion at four months (d=0.21).
Discussion
The feasibility and preliminary effectiveness of this innovative family intervention in 
promoting stress management and a positive QOL for the BMT population was supported. 
The intervention was based on exploratory research designed to identify and understand the 
specific issues this population confronts when a family member undergoes BMT. (7-10) It is 
brief and covers the treatment trajectory prior to hospitalization through four months post-
discharge, which is a particularly stressful and critical period. Furthermore, it has been 
developed to be translatable to the clinical setting.
There is growing interest in the role QOL may play in the successful outcome of BMT. (21) 
Particularly relevant to QOL was the finding of this study that although recipients spent 
much of their time in the hospital during the study trajectory, and therefore received less 
direct intervention than other family members, recipients in the intervention group were the 
only participants to experience less emotional distress --- possibly feeling the intervention 
would assist their families in navigating the stress resulting from their illness and treatment. 
They also expressed an increased sense of family cohesiveness as did the caregivers.
There was considerable concern on the part of professionals about including children in the 
study, however, no parents reported that their children became unduly upset and they readily 
participated in the data collection interviews sometimes sharing more than we requested. 
Talking with them by phone may have also increased their comfort level. In addition, Parents 
indicated in their evaluations that the intervention facilitated knowing how to help their 
children.
Open communication within the family and limiting the use of avoidance coping were 
emphasized. BMT recipients in the intervention group used less avoidance coping than those 
in the control group, and this was also true for children receiving the intervention. Notably, 
these children decreased the frequency with which they used this strategy across the 
trajectory. This is particularly important as research findings have shown family members 
tend to withdraw from each other in crisis situations for fear of increasing others’ distress. 
(22)
The results of this trial indicate caregivers were not only the most highly distressed, they 
also benefitted least from the intervention despite an individual session during 
hospitalization. Therefore, future development needs to increase the intervention intensity 
for caregivers, as they are central to maintaining family stability and facilitating the recovery 
of the recipient. Exploratory analyses indicated when these dyads provided each other with 
mutual support they both were less distressed (9); therefore, interventions to facilitate 
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mutual support within the caregiver/recipient dyad could promote more positive adaptation 
for the caregiver in particular.
Conclusions
The sample size of this feasibility study was limited, consequently the effect sizes were also 
modest; however, the intervention had a positive impact on one or more dimensions of the 
adaptation of each family member as indicated by statistical findings. Particularly important 
were indications of acceptance and participant satisfaction with 97% of caregivers and 
recipients responding they would recommend the intervention to others. Furthermore, it is 
translatable and can also be conducted by health professionals who are readily available in 
the clinical setting. No studies of family focused interventions incorporating both parents 
and children coping with the crisis of a life-threatening illness of a family member have been 
reported to date, yet, our exploratory research indicates no family member is left untouched, 
and each stands to benefit from the intervention.
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Figure 1. 
A Theoretical Model of Adaptation to BMT within the Family Context
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Table 4
Sample Sizes for BMT Recipients and Caregivers at Each Data Point for Both Groups
Family Member Visit Control (N=) Intervention (N=)
Caregiver Baseline 29 31
1-Month Post 26 19
4-Months Post 24 16
Child Baseline 27 31
1-Month Post 25 22
4-Months Post 23 16
Recipient Baseline 29 31
1-Month Post 25 19
4-Months Post 24 15
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